Evolution of antihypertensive combined therapy: from depressin of academician A. L. Myasnikov to modern multi-component drugs

The article shows the historical background to the emergence and subsequent development of combined antihypertensive therapy from creation of a multi-component drug to modern fixed combinations as the most effective approach in the treatment of hypertension (HTN). The authors consider that Russian scientist therapist academician of the USSR Academy of medical Sciences A. L. Myasnikov, has priority in the development of fixed drug combination concept, created depressin powder. The development of pharmacology as a science and the achievements in pharmaceutical technologies contributed to the expansion of possible drugs combination for HTN treatment, and the discovery of new diverse pathophysiological mechanisms implemented in this pathology led to the understanding of the need for combined drugs in clinical practice. The advantages of combination HTN therapy versus monotherapy include rapid achievement of the target blood pressure level, low frequency of tachyphylaxis, longer-lasting antihypertensive effect, no need to change drugs, higher compliance, effective organoprotection and cardiovascular risk reduction, positive and/or neutral effects on the main parameters of metabolism, reduced frequency and severity of side effects. Taking into account these facts, as well as the wide prevalence of HTN in the population, its high medical and social significance, the key role in atherosclerosis, it is necessary to develop new combined domestic drugs for the treatment of HTN and their inclusion in the list of vital medicines, increasing the availability of these drugs for the population on the basis of preferential programs.

1. Iskakov EB. Epidemiology of cardiovascular diseases. Meditsina i Ekologija = Medicine and Ecology. 2017;2:19–28. In Russian.

2. Mjasnikov AL. Hypertension and atherosclerosis. Monograph. Moskva. Medicina. 1965. 616 p. In Russian.

3. Order of the USSR Ministry of Health of September 5, 1985 № 1175 “On measures to strengthen the prevention of hypertension” [Internet]. Available from: https://base.garant.ru/4174765/. In Russian.

4. Sammul S, Jensen-Urstad M, Johansson J, Lenhoff H, Viigimaa M. Psychosocial factors and personality traits and the prevalence of arterial hypertension among 35- and 55-year-old men and women in Sweden and Estonia: a SWESTONIA Longitudinal Study. High Blood Press Cardiovasc Prev. 2019;26(6):475–482. doi:10.1007/s40292-019-00348-y

5. Arterial hypertension. Report of a WHO expert committee. World Health Organ Tech Rep Ser. 1978;(628):7–56.

6. Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb C et al.2017ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018;71(6):1269–1324. doi:10.1161/HYP.00000000000000665

7. Mjasnikov AL. Fundamentals of diagnosis and private pathology (propaedeutics) of internal diseases. M.: Medgiz, 1952. 680 p. In Russian.

8. Coronary artery disease. Monograph ed IE Ganelina. L.: Meditsina, 1977. 360 p. In Russian.

9. Jonash V. Clinical cardiology. Monograph. Prague. State Publishing house of medical literature of Czechoslovakia. 1968. 1047 p. In Russian.

10. Medicinal care in the system of Soviet health care (The main directions of development). Repl ed VI Kant. Chisinau: Stiincea, 1982. 159 p. In Russian.

11. Safonov AG. Medical assistance to the population in the RSFSR. M.: Medgiz, 1961. 368 p. In Russian.

12. Avakyan VM. Differentiated treatment of patients with hypertension in its various stages. Zhurnal Eksperimental’noy i Klinicheskoy Meditsiny = J Ex Clin Med. 1964;4(5):21–30. In Russian.

13. Handbook of clinical pharmacology and pharmacotherapy. Ed IS. Chekman, AP Peleshhuk, OA Pjatak. Kiev: Zdorov'e, 1987. 736 p. In Russian.

14. Müller JM, Schlittler E, Bein HJ. Reserpin, der sedative Wirkstoff aus Rauwolfia serpentina Benth. Experientia. 1952;8:338. doi:10.1007/BF02174406

15. Beermann B, Groschinsky-Grind M, Rosen A. Absorption, metabolism, and excretion of hydrochlorothiazide. Clin Pharmacol Ther J. 1976;5(1):531–537.

16. Cressman MD, Gifford RW. Controversies in hypertension: mild hypertension, isolated systolic and the choice of a step one drug. Clin Cardiol. 1983;6(1):1–10.

17. Shelagurov AA. Propaedeutics of internal diseases. M.: Medicina, 1975. 480 p. In Russian.

18. Nesterov VS. Clinic of heart and vascular diseases. Kiev. Zdorov’e. 1971. 535 p. In Russian.

19. 70 years of Soviet health care. Ed EI Chazov. M.: Medicinа, 1987. 512 p. In Russian.

20. Health standardization. Overcoming contradictions in legislation, practice, ideas. Ed NB Naygovzina, VB Filatov, OA Borozdin, NA Nikolaev. M.: GEOTAR-Media, 2015. 208 p. In Russian.

21. The incidence of urban population and standards of treatment and preventive care. Ed. by prof ID Bogatyrev. M.: Meditsina, 1967. 488 p. In Russian.

22. The Law of the Russian Soviet Federative Socialist Republic on Health Care. M.: Blankazidat, 1971. 24 p. In Russian.

23. Chernorutsky MV. Diagnosis of internal diseases. L.: Medgiz, 1954. 660 p. In Russian.

24. Abdullaev RA. Clinical lectures on current issues of cardiology. Tashkent: Meditsina, 1980. 303 p. In Russian.

25. Golikov AP. Crises in hypertension yesterday and today. Arterial’naya Gipertenziya = Arterial Hypertension. 2004;10(3):147–151. doi:10.18705/1607419X-2004-10-3-147-151. In Russian.

26. Messerli FH, Grossman E, Goldbourt U. Are beta-blockers efficacious as first-line therapy for hypertension in the elderly? A systematic review. J Am Med Assoc. 1998;279(23):1903–1907. doi:10.1001/jama.279.23.1903

27. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure-lowering treatment on cardiovascular outcomes and mortality: 14 — effects of different classes of antihypertensive drugs in older and younger patients: overview and metaanalysis. J Hypertens. 2018;36(8):1637–1647. doi:10.1097/HJH.0000000000001777

28. Saklayen MG, Deshpande NV. Timeline of history of hypertension treatment. Front Cardiovasc Med. 2016;3:3. doi:10.3389/fcvm.2016.00003

29. Chazova IE, Ratova LG. Hypertension: from AL. Myasnikov to the present day. Kardiologicheskij Vestnik. 2010;5(1):5–10. In Russian.

30. Konradi AO. Conservative drug therapy of patients with resistant arterial hypertension is a time of compromise. Medicinskij Sovet = Medical Advice. 2013;(9): 17–25. doi:10.21518/2079-701X-2013-9-17-25. In Russian.

31. Konradi AO. New in non-drug and drug treatment of hypertension in 2013 (review of recommendations for diagnosis and treatment of hypertension ESH/ESC2013). Arterial’naya Gipertenziya = Arterial Hypertension. 2014;20(1):34–37. doi:10.18705/1607419X-2014-20-1-34-37. In Russian.

32. Byrd JB, Bakris G, Jamerson K. The Contribution of the ACCOMPLISH Trial to the Treatment of Stage 2 Hypertension. Curr Hypertens Rep. 2014;16(3):419. doi:10.1007/s11906-014-0419-y

33. Vaulin NA. Combination therapy of arterial hypertension: focus on unfixed combinations. Consilium Medicum. 2011;13(5):36–42. In Russian.

34. Konradi AO. HYVET study — new about the old. Arterial’naya Gipertenziya = Arterial Hypertension. 2008;14(4):397–401. doi:10.18705/1607–419X-2008-14-4-397-401. In Russian.

35. Nedogoda SV. Results of the HYVET study: implications for clinical practice. Cardiovascular Therapy and Prevention. 2008;7(5):76–80. In Russian.

36. Patel DK, Strong J. The pleiotropic effects of sodiumglucose cotransporter-2 inhibitors: beyond the glycemic benefit. Diabetes Ther. 2019;10(5):1771–1792. doi:10.1007/s13300-01900686-z

37. Sviryaev YuV. Combination therapy of hypertension-is it time to “polypill”? Arterial’naya Gipertenziya = Arterial Hypertension. 2009;15(4):458–461. doi:10.18705/1607419X-2009-15-4-458-461. In Russian.

38. Baryshnikova GA, Chorbinskaja SA, Stepanova II, Ljalina SV. Poliphilus as a means to increase the effectiveness of treatment patients with high cardiovascular risk. Trudnyj Pacient = Difficult Patient. 2015;7:6–11. doi:10.26442/2075-1753_19.10.13-18. In Russian.

39. Wald NJ, Law MR. A strategy to reduce cardiovascular disease by more than 80 %. Br Med J. 2003;326(7404):1419–1423. doi: 10.1136/bmj.326.7404.1419.

40. 2018 ESC/ESH Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH). Eur Heart J. 2018;39(33):3021–3104. doi:10.1093/eurheartj/ehy339